An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516293-29-01

Acronym

ASTX727-06

Enrollment

100

Registered

2024-10-04

Start date

2022-03-17

Completion date

Unknown

Last updated

2026-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid lymphoma (AML), chronic myelomonocytic leukemia (CMML) or solid tumors, myelodysplastic syndrome (MDS)

Brief summary

Safety as measured by AEs

Interventions

DRUGASTX727

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Safety as measured by AEs	—

Countries

Austria, Bulgaria, Germany, Hungary, Poland, Romania, Slovakia, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026